Ron Leuty

1 week ago | bizjournals.com | Ron Leuty

Preview this article 1 minThe funding includes a number international venture capital firms and venture units of drug makers Novo Nordisk A/S, Sanofi SA and Asaha Kasei. Leaders of a small Bay Area company have long believed their way of replacing a piece of a sugar chain on proteins critical to muscle control can bring a much-needed therapy to people with a rare, potentially deadly genetic disorder. The problem was perfecting how to uniformly deliver the therapy. Glycomine Inc.

1 week ago | bizjournals.com | Ron Leuty

The company hopes to push the rare-disease treatment toward FDA approval next year. Four months after ditching its lead drug, a small Peninsula biotech with less than $40 million on hand hopes to rev up investor interest anew with a late-stage drug targeting patients with a deadly rare genetic disease. But investors initially Tuesday didn't take to the reset by Spruce Biosciences Inc.

1 week ago | bizjournals.com | Ron Leuty

Preview this article 1 minThe company's newly built home had been empty for more than a year. A year after raising $105 million, a young biotech company assembled another $90 million and found new digs on the Peninsula as it targets itch, eczema and other conditions where the immune system goes awry. Attovia Therapeutics will use its Series C round, led by Deep Track Capital and involving drugmaker Sanofi SA's venture unit, to push its lead drugs through mid-stage clinical trials.

1 week ago | bizjournals.com | Ron Leuty

Courtesy of Third Harmonic BioPreview this article 1 minThree recent moves show how stalled drug developers are funneling cash back to investors, either as they close up shop or pursue new strategies. Amid a four-year biotech downturn that has led companies to cut jobs, programs and real estate, some companies are opting to unload assets, return cash to shareholders or fund new directions.

1 week ago | bizjournals.com | Ron Leuty

Preview this article 1 minThe company and a bankruptcy court trustee have different approaches for protecting consumers' DNA information. A showdown between competing plans for overseeing precious genetic data from 15.5 million customers in the bankruptcy case of testing company 23andMe could climax this month.